Sign In
Buy ZYME
$24.35
+0.240 (+1.00%)
At Close: Jun 03, 2026
Investor Slashes $70 Million From Zymeworks as Stock Jumps 60% in a Year
12:53pm, Sunday, 22'nd Feb 2026
Redmile Group sold 3,214,096 ZYME shares, estimated at $70.10 million based on quarterly average prices. Meanwhile, the quarter-end value of the Zymeworks stake decreased by $50.35 million, reflecting
Zymeworks (NYSE:ZYME) and Zomedica (OTC:ZOMDF) Critical Review
01:52am, Friday, 13'th Feb 2026
Zomedica (OTC: ZOMDF - Get Free Report) and Zymeworks (NYSE: ZYME - Get Free Report) are both small-cap manufacturing companies, but which is the better stock? We will contrast the two companies based
Zymeworks To Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on March 2, 2026
06:00am, Thursday, 12'th Feb 2026
VANCOUVER, British Columbia, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pip
Contrasting Zymeworks (NASDAQ:ZYME) and Generex Biotechnology (OTCMKTS:GNBT)
01:44am, Friday, 06'th Feb 2026
Zymeworks (NASDAQ: ZYME - Get Free Report) and Generex Biotechnology (OTCMKTS:GNBT - Get Free Report) are both small-cap manufacturing companies, but which is the better business? We will compare the
Zymeworks Announces Participation in Upcoming Investor Conferences
06:00am, Tuesday, 27'th Jan 2026
VANCOUVER, British Columbia, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pip
Mark Hollywood Sells 6,120 Shares of Zymeworks (NYSE:ZYME) Stock
05:16am, Thursday, 15'th Jan 2026
Zymeworks Inc. (NYSE: ZYME - Get Free Report) COO Mark Hollywood sold 6,120 shares of the company's stock in a transaction that occurred on Monday, January 12th. The stock was sold at an average price
Zymeworks Inc. (ZYME) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
09:15pm, Wednesday, 14'th Jan 2026
Zymeworks Inc. (ZYME) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Zymeworks Announces Leadership Appointments and Transitions to Align with Evolution of Corporate Strategy
06:00am, Monday, 12'th Jan 2026
VANCOUVER, British Columbia, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pip
HERIZON-GEA-01 Trial Highlights Zymeworks' Path To $440M Milestones And Growth
03:59am, Monday, 12'th Jan 2026
Zymeworks delivered strong Phase 3 HERIZON-GEA-01 results for Ziihera, achieving over two years median overall survival in HER2-positive GEA. ZYME stands to receive up to $440 million in milestone pay
Zymeworks Outlines Strategic Priorities and Outlook for 2026
06:00pm, Sunday, 11'th Jan 2026
VANCOUVER, British Columbia, Jan. 11, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pip
Jazz Pharmaceuticals' Drug Extends Survival Past Two Years in Advanced Stomach Cancer Trial
01:12pm, Wednesday, 07'th Jan 2026
Jazz Pharmaceuticals reported Phase 3 trial results showing Ziihera helped patients with advanced HER2-positive stomach cancer live longer, with some treatments pushing survival beyond two years.
Zymeworks Inc. (NYSE:ZYME) Receives Consensus Rating of “Buy” from Analysts
01:30am, Wednesday, 07'th Jan 2026
Zymeworks Inc. (NYSE: ZYME - Get Free Report) has been given a consensus recommendation of "Buy" by the eleven ratings firms that are covering the firm, Marketbeat.com reports. Eleven research analyst
VANCOUVER, British Columbia, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pip
Zymeworks (NYSE:ZYME) Insider Paul Andrew Moore Sells 20,110 Shares of Stock
05:20am, Tuesday, 06'th Jan 2026
Zymeworks Inc. (NYSE: ZYME - Get Free Report) insider Paul Andrew Moore sold 20,110 shares of the company's stock in a transaction on Monday, January 5th. The stock was sold at an average price of $25
Zymeworks (NYSE:ZYME) EVP Jeffrey Smith Sells 10,538 Shares
05:20am, Tuesday, 06'th Jan 2026
Zymeworks Inc. (NYSE: ZYME - Get Free Report) EVP Jeffrey Smith sold 10,538 shares of the company's stock in a transaction on Monday, January 5th. The shares were sold at an average price of $25.10, f
